New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
09:17 EDTOC, CLRX, MACK, DRI, ORCL, ETE, SWHC, KMX, ABBV, TRGP, NGLS, SNY, FDO, SHPGOn The Fly: Pre-market Movers
HIGHER: Shire (SHPG), up 16% after disclosing it rejected a takeover offer from AbbVie (ABBV). Bloomberg reported that AbbVie may increase its takeover offer following the rejection. Shares of AbbVie are also up 2% following the news... CarMax (KMX), up 16% after Q1 earnings beat analyst's consensus... Family Dollar (FDO), up 2.4% after Carl Icahn sent a letter to CEO urging an immediate sale. LOWER: Oracle (ORCL), down 5% after downgraded at Citigroup following the company's Q4 earnings results... Darden (DRI), down 4% after reporting Q4 earnings... Merrimack Pharmaceuticals (MACK), down 11% after announcing that it has reached an agreement with Sanofi (SNY) to regain worldwide rights to develop and commercialize MM-121... Smith & Wesson (SWHC), down 8% after guidance for Q1, FY15 miss expectations... Targa Resources Partners (NGLS), down 9.3% after downgraded at Wunderlich following news that the company's takeover talks with Energy Transfer Equity (ETE) ended without a deal. Targa Resources (TRGP), the parent of Targa Resources Partners, is down 9% after the news.. Owens Corning (OC), down 6% after cutting FY14 adjusted EBIT view... Hercules Offshore (HERO), down 6.8% after downgraded at Iberia... AK Steel (AKS), down 4.5% after giving Q2 EPS guidance.
News For ORCL;SHPG;ABBV;DRI;FDO;KMX;MACK;SNY;SWHC;CLRX;NGLS;ETE;OC;TRGP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 15, 2015
10:55 EDTETEJANA Partners gives quarterly update on stakes
Subscribe for More Information
10:29 EDTABBV, SNYAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:45 EDTABBVAbbVie reports FDA orphan designation for Humira in treatment of HS
Subscribe for More Information
May 14, 2015
13:12 EDTABBVAbbVie granted orphan status for Humira
Subscribe for More Information
10:41 EDTABBVAnalysts upbeat on Amgen's Kyprolis after ASCO abstracts
Subscribe for More Information
10:00 EDTKMXOn The Fly: Analyst Initiation SummaryT
Today's noteworthy initiations include: Advaxis (ADXS) initiated with a Buy at MLV & Co.... Akebia (AKBA) initiated with a Buy at Brean Capital... CarMax (KMX) initiated with a Buy at Sterne Agee CRT... Coach (COH) initiated with a Neutral at Wedbush... Euronav NV (EURN) initiated with an Outperform at Credit Suisse... Franco-Nevada (FNV) initiated with an Outperform at Macquarie... Kate Spade (KATE) initiated with an Outperform at Wedbush... Lumber Liquidators (LL) initiated with a Perform at Oppenheimer... Michael Kors (KORS) initiated with a Neutral at Wedbush... National Instruments (NATI) initiated with an Overweight at Stephens... Royal Gold (RGLD) initiated with an Outperform at Macquarie... Spectra Energy Partners (SEP) initiated with a Buy at Janney ... Spectra Energy (SE) initiated with a Buy at Janney Capital... Tribune Publishing (TPUB) initiated with a Buy at Sterne Agee CRT.
09:09 EDTABBVBristol-Myers down 1.3% after release of ASCO abstracts
Subscribe for More Information
06:46 EDTKMXCarMax initiated with a Buy at Sterne Agee CRT
Subscribe for More Information
05:38 EDTKMXCarMax initiated with a Buy at Sterne Agee CRT
Subscribe for More Information
May 13, 2015
13:12 EDTABBVSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
11:12 EDTTRGPEnergy MLPs weak despite Williams deal for Williams Partners
Subscribe for More Information
10:02 EDTMACKOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A.O. Smith (AOS) initiated with a Hold at Gabelli... Bellicum Pharmaceuticals (BLCM) initiated with a Neutral at Guggenheim... Criteo (CRTO) initiated with a Hold at Evercore ISI... FleetCor (FLT) initiated with a Buy at Monness Crespi... Franco-Nevada (FNV) initiated with a Buy at Canaccord... Horizon Technology (HRZN) initiated with an Outperform at Oppenheimer... Merrimack (MACK) initiated with a Buy at Guggenheim... Mobileye (MBLY) initiated with a Sector Weight at Pacific Crest... Monroe Capital (MRCC) initiated with an Outperform at Oppenheimer... Royal Gold (RGLD) initiated with a Hold at Canaccord... Silver Wheaton (SLW) initiated with a Buy at Canaccord... U.S. Concrete (USCR) initiated with a Buy at Stifel... Ziopharm (ZIOP) initiated with a Neutral at Guggenheim.
09:44 EDTTRGPMLPs that could trade up on Williams, Williams Partners news, says Credit Suisse
Credit Suisse said Plains GP Holdings (PAGP), Targa Resources (TRGP), NuStar (NSH), Western Gas Equity (WGP) could trade up on the Williams (WMB)/Williams Partners (WPZ) merger news.
09:11 EDTMACKMerrimack has a conference call hosted by JPMorgan
JPMorgan Analyst Rama will host a conference call with CEO Bob Mulroy on May 15 at 10 am.
07:31 EDTSNYHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
07:05 EDTSNYSanofi exercises option on therapeutic program with Selecta Biosciences
Selecta Biosciences., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi. November 2012, Selecta announced that they had formed a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life threatening allergies. Under the agreement, Sanofi obtained a first exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies and celiac disease. With the exercise of this option by Sanofi, Selecta and Sanofi now have two initiatives actively advancing immune tolerance treatments under the terms of the 2012 agreement. In October 2014, Selecta and JDRF announced another collaboration with Sanofi to research novel antigen-specific immune therapies for Type 1 Diabetes.
06:30 EDTMACKMerrimack initiated with a Buy at Guggenheim
Target $15.
May 12, 2015
07:52 EDTSHPGLeerink to hold a tour
Subscribe for More Information
May 11, 2015
08:48 EDTDRIPanera Bread appoints Drew Madsen President effective May 11
Subscribe for More Information
06:33 EDTKMXCarMax management to meet with Oppenheimer
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use